Combination of drug activating TXNIP with imatinib effectively suppresses the development of CML-like myeloproliferative disease in mice, which provides a rationale for treating patients with CML with minimal residual disease. This evidence concerns the gene TXNIP and chronic myelogenous leukemia, BCR-ABL1 positive.